{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["ESO-T01"]],"indication":"relapsed/refractory multiple myeloma","name":"NCT06691685","nct_id":"NCT06691685","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06691685. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.","label":"ESO-T01 Injection","type":"EXPERIMENTAL"}],"collaborators":["Shenzhen Pregene Biopharma Co., Ltd."],"completion_date":{"date":"2027-11-01","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":24,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"ESO-T01 Injection","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-22","lead_sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","official_title":"A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.","overall_status":"SUSPENDED","phases":["EARLY_PHASE1"],"primary_completion_date":{"date":"2027-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Cytokine release syndrome (CRS)","timeFrame":"up to Day 28 post-infusion"},{"measure":"Dose-limiting toxicities (DLTs)","timeFrame":"Dose-limiting toxicities (DLTs) are evaluated between the infusion and 28 days post-infusion."},{"measure":"immune cell-associated immune effector cell-associated neurotoxicity syndrome (ICANS)","timeFrame":"up to Day 28 post-infusion"},{"measure":"Treatment-associated adverse effects (AEs)","timeFrame":"up to 2 years after treatment of ESO-T01"}],"references":[{"citation":"Xu J, Liu L, Xie W, Su L, Wang W, Li C, Liu Q, Kang Y, Zhang Y, Luo W, Huang Z, Zhang C, Sun C, Hu Y, Mei H. Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma. Nat Med. 2026 Oct 6. doi: 10.1038/s41591-026-04704-z. Online ahead of print.","pmid":"42839103","type":"DERIVED"}],"start_date":{"date":"2024-11-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.","url":"https://clinicaltrials.gov/study/NCT06691685"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06691685"}